Monitor for future 8-K or 6-K filings announcing actual offering terms. Shelf registrations often precede at-the-market (ATM) offerings or follow-ons, which could pressure shares if significantly dilutive. Given IMA's small $53M market cap, even a modest offering could materially impact the stock.
IMA drugs
IMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $4.55entry
- T+1 · 7mo ago +4.40%α +4.33% · $4.75
- T+5 · 7mo ago +32.97%α +28.83% · $6.05
- T+20 · 7mo ago +25.60%α +16.62% · $5.72
- T+60 · 5mo ago +26.81%α +13.34% · $5.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImageneBio, Inc. (IMA) has an effective SEC registration (Form S-3) allowing it to sell unspecified securities. This is a shelf registration, not an IPO, meaning the company can now issue shares at any time, creating potential dilution overhang. No offering size, pricing, or use of proceeds details are disclosed in this filing.
Key Facts
- ImageneBio, Inc. (IMA) has received SEC effectiveness for registration statement 333-290108.
- This is a shelf registration (S-3), not an IPO, enabling the company to sell securities from time to time.
- No specific offering size, share count, price, or timing is disclosed in the filing.
- The effectiveness date was April 3, 2026, with the filing updated on April 6, 2026.
- The company was formerly known as Ikena Oncology, Inc. (name changed December 8, 2020).
Financial Impact
Undisclosed, potential future dilution depending on offering size and price
Risk Factors
- Future dilution risk if the company issues equity under this shelf
- Lack of transparency on offering size or timing creates uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001080 |
| Document: 9999999995-26-001080-index.html | 9999999995-26-001080 |
| Document: 9999999995-26-001080.txt | 9999999995-26-001080 |
Track record
10 reports on IMA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Viewing Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers